XTL Biopharmaceuticals Ltd. (XTLB)
XTL Biopharmaceuticals Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ramat Gan, TA, IL. The stock last traded at $2.79, up 5.28% on the session, giving a market capitalisation of $2.6M. On trailing twelve-month figures it carries a trailing P/E of -0.88, a net margin of 0.0%. Its beta of 0.46 implies it has historically moved less than the broad market.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd. is most often compared with the following Healthcare names: